Pilot go to benchmark constant bioprocessing innovation in cultivated meat production. After amazing lead to pharma, Stämm partners with SuperMeat broadening into the food tech market, helped with by Varana Capital.
TEL AVIV, Israel and BUENOS AIRES, Argentina, Feb. 4, 2025/ PRNewswire/– The business partnered to even more improve SuperMeat’s cultivated chicken meat procedure with Stämm’s unique bioreactor. Varana Capital, a shared financier in both business, offers tactical assistance to advance this collaboration, showing their self-confidence in its capacity.
Stämm, an innovator in biopharma production, broadens to food-tech after appealing outcomes with stem cell culture. They utilize their Bioprocessor, an automatic constant bubble-free-bioreactor offering unmatched expense savings and 15x increased volumetric performance in biologics production.
SuperMeat, a cultivated meat business, became a perfect very first partner for a pilot at their center, following its current development in attaining expense parity for cultivated chicken production at $ 11.79 per pound, integrating unmatched speed and high yields of muscle and fat straight from animal cells.
” In the coming months, a joint group will criteria and examine how to incorporate our Bioprocessor into SuperMeat’s end-to-end production procedure. We are delighted to see the outcomes of this distinct alliance”, stated Yuyo Llamazares Vegh, Stämm’s CEO.
The cooperation intends to improve muscle fiber development, elongation, and blend into fully grown muscle tissue, while likewise boosting adipocyte development, to produce natural whole-cut pieces. These advancements are anticipated to lead to a substantial boost in item mass, allowing the production of affordable cultivated meat which carefully mirrors traditional meat structure and taste.
” This collaboration shows how complementary innovations can integrate to drive development in the cultivated meat market”, stated Ido Savir, CEO of SuperMeat. “By unifying our innovations, we develop a path to entire cut cultivated meat items that provide exceptional quality and customer appeal.”
The business will utilize their outcomes to establish a procedure scaling design and a research study for the economics of the procedure and centers. Speculative metrics will show the capacity for Stämm’s innovation to decrease the expense of items through increased culture media performance for biomass production.
With the alternative protein market predicted to rise to $ 290 billion by 2035, according to BCG and Blue Horizon report, it represents a significant organization chance.
“ Israel’s remarkable entrepreneurial spirit and technological expertise make it a perfect financial investment location for advancing the transformation in alternative protein production, both by presenting Stamm’s biomanufacturing development into its environment and by integrating it with Supermeat’s resourcefulness,” stated Ezra Gardner, Varana Capital Co-Founder and CIO.
About the Partners
Stämm establishes constant bioreactor innovation to change biomanufacturing. Its options improve performance and scalability, allowing partners throughout markets worldwide. https://www.stamm.bio/
SuperMeat, a leader in cultivated chicken meat grown straight from chicken cells, is changing the food system with sustainable, scalable, and available alternative proteins. https://supermeat.com/
About Varana Capital
Denver and Tel Aviv based Varana Capital purchases visionary leaders and promotes worldwide effect through tactical collaborations throughout public and economic sectors. https://varanacapital.com/
Media Contact:
Kelci Jones kmj@varanacapital.com
View initial material to download multimedia: https://www.prnewswire.com/news-releases/stamm-and-supermeat-collaborate-to-accelerate-cultivated-meat-biomanufacturing-with-support-from-mutual-investor-varana-capital-302367321.html
SOURCE Varana Capital, LLC
Market News and Data gave you by Benzinga APIs